| Q83232973 | 8 Inhibitors |
| Q52431401 | An ADAM-10 dependent EPCR shedding links meningococcal interaction with endothelial cells to purpura fulminans. |
| Q42086189 | Antithrombin III (AT) and recombinant tissue plasminogen activator (R-TPA) used singly and in combination versus supportive care for treatment of endotoxin-induced disseminated intravascular coagulation (DIC) in the neonatal pig. |
| Q73437813 | Chromatographic purification and properties of a therapeutic human protein C concentrate |
| Q34577529 | Clinical trials of immunomodulatory therapies in severe sepsis and septic shock |
| Q43865671 | Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study |
| Q35794980 | Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis |
| Q36607385 | Drotrecogin alfa (activated) in the treatment of severe sepsis |
| Q35059326 | Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis |
| Q37609202 | Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis |
| Q34779800 | Drotrecogin alfa: a new approach in the treatment of severe sepsis |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q44899996 | Early treatment with activated protein C for meningococcal septic shock: case report and literature review |
| Q35562846 | Hematologic Abnormalities in Severe Neonatal Necrotizing Enterocolitis: 25 Years Later |
| Q34153375 | Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients |
| Q36042279 | New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin |
| Q37067386 | Non Activated Protein C Supplementation in Septic Pediatric Hematological Patients |
| Q80672463 | Plasma derived protein C in severe sepsis: report of two cases |
| Q34219618 | Protein C replacement in severe meningococcemia: rationale and clinical experience |
| Q41687756 | Sepsis-associated Purpura Fulminans International Registry--Europe (SAPFIRE) |
| Q37290652 | Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications |
| Q40396604 | Successful treatment with Protein C of febrile neutropenia in pediatric patients during cancer therapy |
| Q35128911 | Such stuff as dreams are made on: mediator-directed therapy in sepsis |
| Q35548184 | The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C |
| Q52951509 | [Coagulation inhibitors in severe sepsis: state of the art]. |